Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
T. Blum, J. Kollmeier, S. Griff, T. Weiss, W. Ammenwerth, S. Delis, W. Nehls, T. Sabha, S. Thiel, N. Schönfeld, T. T. Bauer (Berlin, Germany). Prognostic impact of histology and treatment modalities in malignant mesothelioma. Eur Respir J 2013; 42: Suppl. 57, 3079

Member's Comments

No comment yet.

Related content which might interest you: Prognostic value of treatment outcomes patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Prognostic characteristics of malignant pleural mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Pre-therapeutic staging and prognostic factors in malignant pleural mesothelioma patients Source: Annual Congress 2009 - Malignant pleural mesothelioma guidelines Year: 2009 Clinical and morphological prognostic factors in patients with malignant pleura mesothelioma (MPM) Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Prognostic factors in diffuse malignant pleural mesothelioma Source: Eur Respir J 2003; 22: Suppl. 45, 62s Year: 2003 Prognostic factors in diffuse malignant pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 755s Year: 2007 Prognostic significance of pretreatment clinical and laboratory characteristics in patients with diffuse malignant pleural mesothelioma Source: Eur Respir J 2006; 28: Suppl. 50, 784s Year: 2006 Management of malignant mesothelioma Source: ERS Skills Course 2018 - Practical Pleural Skills Year: 2018 Diagnosis and staging of malignant pleural mesothelioma Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020 Contemporary management of malignant mesothelioma Source: Annual Congress 2004 - PG20 - State-of-the art in management of pleural diseases Year: 2004 The analysis of clinicopathological characteristics and prognosis of malignant pleural mesothelioma Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013 Therapeutic outcome and prognostic factors in patients with pleural mesothelioma Source: Eur Respir J 2005; 26: Suppl. 49, 73s Year: 2005 Clinical characteristics, treatment and survival outcomes in malignant mesothelioma Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012 Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010 Haematologic parameters and their prognostic impact in malignant pleural mesothelioma Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Predicting survival in malignant mesothelioma Source: Eur Respir J 2011; 38: 1420-1424 Year: 2011 Chemotherapy for treatment of malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004 Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005